fbpx

Drs. François Ferré & Magda Marquet

Dr. François Ferré is the co-CEO of ALMA LifeSciences LLC, an investment and consulting firm with a focus on prevention. He is also the Co-Chairman and co-Founder of AltheaDx, a privately-held company (spinoff of Althea Technologies) focusing on the development of pharmacogenomic tests. Dr. Ferre was the CEO of AltheaDx from 2010 to June 2013. Prior to AltheaDx, Dr. Ferré co-founded Althea Technologies and served as co-CEO from 1998 until 2008. Althea was successfully acquired by Ajinomoto in 2013. He was a Director of Althea Technologies until April 2013 and was a Director of Ajinomoto-Althea until 2019. He also currently serves on the board of a number of additional private companies such as Agendia and Neuralace. He is a Managing Director of Mesa Verde Venture Partners and he is a Board member of La Jolla Institute of Allergy and Immunology. Dr. Ferré was the winner of the 2005 E&Y Entrepreneur of the Year award in the Life Sciences category. Dr. Ferré is a leader in gene quantification and biomarker development and published several authoritative reviews on these topics, including the co-edition of a bestseller book on PCR with Nobel Prize winner, Dr. Kary Mullis. He received his PhD in molecular oncology from the Pasteur Institute, France and did his post-doctoral training at the University of California, San Diego. 

Dr. Magda Marquet has built, led and commercialized multiple life science companies. She is the co-founder of AltheaDx, a commercial stage, precision medicine company with the world’s leading pharmacogenomics test for anxiety and depression, and ALMA Life Sciences, LLC, an early stage investment firm creating and growing innovative healthcare companies. Dr. Marquet co-founded Althea Technologies and, as its co-CEO with full P&L responsibility, led the company to become a leader in the field and a highly profitable, commercial company. As a result, she guided Althea to a successful acquisition by Ajinomoto, a global Japanese company and leader in amino acid technology.
Prior to starting Althea Technologies, Dr. Marquet held several positions in pharmaceutical development in companies such as Vical and Amylin Pharmaceuticals.
She currently serves on the following Boards: Arcturus Therapeutics (ARCT) (Compensation Committee Chair, member of the Audit Committee and Nomination Governance Committee). She also serves on the Board of Pfenex (PFNX) (Nomination and Governance Committee) and she serves on several private companies boards such as Senté and HUYA Biosciences International.

As a former founder and CEO, Dr Marquet has broad operational, fund raising expertise including venture, private equity and venture debt. She also brings expertise in M&A, global commercial development, regulatory strategies and building a winning culture of innovation and strategic growth.
Dr. Marquet holds a Ph.D in Biochemical Engineering from INSA/University of Toulouse, France. She has received numerous prestigious awards throughout her career including the 2005 Regional Ernst&Young Entrepreneur of the Year award in the Life Sciences category, the Athena Pinnacle award, the Director of the Year award (Corporate Governance) from the Corporate Directors Forum and has been inducted into the CONNECT Entrepreneur Hall of Fame.
 

.